Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
Phase 2
Completed
- Conditions
- HIV InfectionsHodgkin's Disease
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-27
- Target Recruit Count
- 27
- Registration Number
- NCT00000626
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath